Pemafibrate (Parmodia, K-877) — Research Compounds Library | RetatrutideCompare

Selective PPAR-α modulator (SPPARMα). Approved in Japan for hypertriglyceridemia; the PROMINENT trial (2022) showed triglyceride lowering but no reduction in cardiovascular events in T2D.